| Radiation dose–volume effects in the brain YR Lawrence, XA Li, I El Naqa, CA Hahn, LB Marks, TE Merchant, ... International Journal of Radiation Oncology* Biology* Physics 76 (3), S20-S27, 2010 | 867 | 2010 |
| Patient-oriented cancer information on the internet: a comparison of wikipedia and a professionally maintained database MS Rajagopalan, VK Khanna, Y Leiter, M Stott, TN Showalter, AP Dicker, ... Journal of Oncology Practice 7 (5), 319-323, 2011 | 128 | 2011 |
| Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities D Urban, A Rao, M Bressel, YR Lawrence, L Mileshkin British journal of cancer 109 (5), 1318-1324, 2013 | 77 | 2013 |
| Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line? YR Lawrence, DT Blumenthal, D Matceyevsky, AA Kanner, F Bokstein, ... Journal of neuro-oncology 105, 1-7, 2011 | 76 | 2011 |
| Quality assurance peer review chart rounds in 2011: A survey of academic institutions in the United States YR Lawrence, MA Whiton, Z Symon, EJ Wuthrick, L Doyle, AS Harrison, ... International Journal of Radiation Oncology* Biology* Physics 84 (3), 590-595, 2012 | 73 | 2012 |
| Splenic infarction: an update on William Osler's observations. MA Lawrence, YR MBBS MRCP, MB Pokroy, MB Berlowitz, MD Aharoni, ... | 70 | 2010 |
| NCI–RTOG translational program strategic guidelines for the early-stage development of radiosensitizers YR Lawrence, B Vikram, JJ Dignam, A Chakravarti, M Machtay, B Freidlin, ... Journal of the National Cancer Institute 105 (1), 11-24, 2013 | 64 | 2013 |
| Improving prognosis of glioblastoma in the 21st century: who has benefited most? YR Lawrence, MV Mishra, M Werner‐Wasik, DW Andrews, TN Showalter, ... Cancer 118 (17), 4228-4234, 2012 | 59 | 2012 |
| Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location T Golan, D Urban, R Berger, YR Lawrence Cancer 119 (16), 3084-3091, 2013 | 56 | 2013 |
| Does choline PET/CT change the management of prostate cancer patients with biochemical failure? J Goldstein, E Even-Sapir, S Ben-Haim, A Saad, B Spieler, T Davidson, ... American Journal of Clinical Oncology 40 (3), 256-259, 2017 | 54 | 2017 |
| Short-and long-term survival in metastatic pancreatic adenocarcinoma, 1993–2013 T Golan, T Sella, O Margalit, U Amit, N Halpern, D Aderka, ... Journal of the National Comprehensive Cancer Network 15 (8), 1022-1027, 2017 | 53 | 2017 |
| Eukaryotic Initiation Factor 2α-a Downstream Effector of Mammalian Target of Rapamycin-Modulates DNA Repair and Cancer Response to Treatment L Tuval-Kochen, S Paglin, G Keshet, Y Lerenthal, C Nakar, T Golani, ... PloS one 8 (10), e77260, 2013 | 53 | 2013 |
| Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas W Shi, JD Palmer, M Werner-Wasik, DW Andrews, JJ Evans, J Glass, ... Journal of neuro-oncology 127, 535-539, 2016 | 52 | 2016 |
| Characterization and outcomes of optic nerve gliomas: a population-based analysis MV Mishra, DW Andrews, J Glass, JJ Evans, AP Dicker, X Shen, ... Journal of neuro-oncology 107, 591-597, 2012 | 50 | 2012 |
| Predictors of radiation oncology resident research productivity JM Gutovich, RB Den, M Werner-Wasik, AP Dicker, YR Lawrence Journal of the American College of Radiology 10 (3), 185-189, 2013 | 48 | 2013 |
| Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial W Shi, YR Lawrence, H Choy, M Werner-Wasik, DW Andrews, JJ Evans, ... Journal of neuro-oncology 118, 313-319, 2014 | 47 | 2014 |
| Lymph node ratio predicts the benefit of post-operative radiotherapy in oral cavity cancer D Urban, I Gluck, MR Pfeffer, Z Symon, YR Lawrence Radiotherapy and Oncology 106 (1), 74-79, 2013 | 47 | 2013 |
| mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer MJ Schiewer, R Den, DT Hoang, MA Augello, YR Lawrence, AP Dicker, ... Endocrine-related cancer 19 (1), 1, 2012 | 47 | 2012 |
| A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas RB Den, M Kamrava, Z Sheng, M Werner-Wasik, E Dougherty, ... International Journal of Radiation Oncology* Biology* Physics 85 (2), 321-328, 2013 | 46 | 2013 |
| Early toxicity predicts long-term survival in high-grade glioma YR Lawrence, M Wang, AP Dicker, D Andrews, WJ Curran, JM Michalski, ... British journal of cancer 104 (9), 1365-1371, 2011 | 46 | 2011 |
